Want to see HK:1873 full AI Analyst Report?
1873 Stock Chart & Stats
HK$1.76
-HK$0.01(-1.20%)
At close: 4:00 PM EST
HK$1.76
-HK$0.01(-1.20%)
Day’s Range― - ―
52-Week RangeHK$1.04 - HK$3.27
Previous CloseN/A
Volume129.00K
Average Volume (3M)10.31M
Market Cap
HK$3.14B
Enterprise ValueHK$4.12K
Total Cash (Recent Filing)HK$1.13B
Total Debt (Recent Filing)HK$1.33B
Price to Earnings (P/E)13.0
Beta2.04
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding2,093,553,500
10 Day Avg. Volume10,852,121
30 Day Avg. Volume10,305,290
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)0.99
Price to Sales (P/S)2.28
P/FCF Ratio44.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.12
Revenue Forecast (FY)HK$2.13B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryReturn to net profits in 2024–2025, combined with mid-30% gross margins and low-teens operating margins, indicates a meaningful recovery in core earnings. Sustained margins improve the company's ability to self-fund R&D, support contract delivery and enhance long-term earnings quality if top-line stabilizes.
Improving LeverageMaterial reduction in debt-to-equity to roughly one-third in 2024–2025 strengthens financial flexibility and lowers interest burden. Improved leverage supports capacity to invest in labs and platforms, making the business more resilient to project timing and reducing refinancing risk over the medium term.
Integrated CRO PlatformAn integrated, platform-based CRO model—covering structure-based discovery, chemistry and biology—creates durable competitive advantages through cross-selling, client stickiness and bundled programs. Platform capabilities support longer-term engagements and milestone-based revenue, enhancing recurring service demand.
Bears Say
Multi-year Revenue DeclineA multi-year top-line decline culminating in an 8.3% fall in 2025 undermines utilization of lab capacity and pricing leverage. Persistent revenue contraction constrains scalable returns from fixed-cost platforms, limits margin expansion and pressures the sustainability of recent profit gains.
Weakening Cash FlowA ~59% YoY decline in free cash flow and falling operating cash in 2025 materially reduce internal funding capacity. Weaker cash generation limits the company's ability to invest in platform upgrades, absorb client payment variability, and maintain liquidity buffers during an ongoing top-line slowdown.
Profitability VolatilityEarnings swung from losses in 2022–2023 to profits in 2024–2025, highlighting volatile profitability. Such swings make forward planning and credit metrics less reliable, increasing dependence on sustaining current profits to preserve balance-sheet strength and raising operational risk during downturns.
Viva Biotech Holdings News
1873 FAQ
What was Viva Biotech Holdings’s price range in the past 12 months?
Viva Biotech Holdings lowest stock price was HK$1.04 and its highest was HK$3.27 in the past 12 months.
What is Viva Biotech Holdings’s market cap?
Viva Biotech Holdings’s market cap is HK$3.14B.
When is Viva Biotech Holdings’s upcoming earnings report date?
Viva Biotech Holdings’s upcoming earnings report date is Aug 26, 2026 which is in 7 days.
How were Viva Biotech Holdings’s earnings last quarter?
Viva Biotech Holdings released its earnings results on Mar 30, 2026. The company reported HK$0.051 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Viva Biotech Holdings overvalued?
According to Wall Street analysts Viva Biotech Holdings’s price is currently Overvalued.
Does Viva Biotech Holdings pay dividends?
Viva Biotech Holdings pays a Notavailable dividend of HK$0.01 which represents an annual dividend yield of N/A. See more information on Viva Biotech Holdings dividends here
What is Viva Biotech Holdings’s EPS estimate?
Viva Biotech Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viva Biotech Holdings have?
Viva Biotech Holdings has 2,093,553,500 shares outstanding.
What happened to Viva Biotech Holdings’s price movement after its last earnings report?
Viva Biotech Holdings reported an EPS of HK$0.051 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.785%.
Which hedge fund is a major shareholder of Viva Biotech Holdings?
Currently, no hedge funds are holding shares in HK:1873
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viva Biotech Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.87%
Trailing 12-Months
Company Description
Viva Biotech Holdings
Viva Biotech Holdings, founded in 2008 and based in Shanghai, China, operates as an investment holding company primarily dedicated to providing comprehensive, structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. Its extensive discovery biology offerings encompass protein expression and purification, structural biology, hit identification, bioassay development, biomolecular interaction analysis, and pharmacokinetic studies. The company also delivers a suite of chemistry services, including medicinal and synthetic chemistry, analytical services, preparative purification, and computer-aided drug design, all supported by robust chemical technology platforms. Viva Biotech further specializes in antibody drug research and development, covering antigen preparation, multi-species antibody discovery, monoclonal antibody production, functional screening and characterization, antibody engineering, and cell line engineering. This work is facilitated by cutting-edge technological platforms such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high-throughput sequencing, computer-aided drug design, HDX-MS, protein crystal structure determination, and SPR technology. Beyond its core service offerings, Viva Biotech provides various biological resources, including cell lines, crystal structures, GPCR proteins, antibodies, and other purified proteins. The company also offers contract development and manufacturing (CDMO) services for small molecule active pharmaceutical ingredients (APIs) and their intermediates. Furthermore, it engages in the trading of APIs, intermediates, and formulations, and operates under an "equity for service" model. Additional services include general research, laboratory facility rentals, project management and bidding assistance, and the sale of chemical compounds.
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―